Amicus Therapeutics FOLD reported first-quarter 2025 adjusted earnings of 3 cents per share, which missed the Zacks Consensus Estimate of 8 cents. The company had reported a loss of 2 cents per ...

The company delivered record DRAM probe-card revenue with solid DDR5 demand coupled with sequential growth in HBM in the fourth quarter of 2024.

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against the other best ...